bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BLUE
- CUSIP: N/A
- Web: www.bluebirdbio.com
Capitalization:- Market Cap: $4.2966 billion
- Outstanding Shares: 40,950,000
Average Prices:- 50 Day Moving Avg: $103.56
- 200 Day Moving Avg: $87.10
- 52 Week Range: $37.05 - $123.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.60
- P/E Growth: 0.23
Sales & Book Value:- Annual Revenue: $11.49 million
- Price / Sales: 342.32
- Book Value: $19.92 per share
- Price / Book: 4.82
Profitability:- EBIDTA: ($250,640,000.00)
- Net Margins: -2,402.03%
- Return on Equity: -35.17%
- Return on Assets: -27.25%
Debt:- Current Ratio: 9.19%
- Quick Ratio: 9.19%
Misc:- Average Volume: 1.01 million shs.
- Beta: 2.13
- Short Ratio: 12.19
Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)
What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
How were bluebird bio's earnings last quarter?
bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($1.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.76) by $0.08. The firm earned $6.83 million during the quarter, compared to analysts' expectations of $1.51 million. bluebird bio had a negative net margin of 2,402.03% and a negative return on equity of 35.17%. View bluebird bio's Earnings History.
When will bluebird bio make its next earnings announcement?
Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?
17 equities research analysts have issued 1 year price objectives for bluebird bio's shares. Their predictions range from $39.00 to $135.00. On average, they expect bluebird bio's share price to reach $98.82 in the next twelve months. View Analyst Ratings for bluebird bio.
What are analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
- 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
- 2. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)
- 3. Cantor Fitzgerald analysts commented, "Updated Data." (6/5/2017)
- 4. Maxim Group analysts commented, "bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM)." (6/2/2017)
Who are some of bluebird bio's key competitors?
Some companies that are related to bluebird bio include Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Sarepta Therapeutics (SRPT), AveXis (AVXS), Axovant Sciences (AXON) and Spark Therapeutics (ONCE).
Who are bluebird bio's key executives?
bluebird bio's management team includes the folowing people:
- Daniel S. Lynch, Independent Chairman of the Board
- Nick Leschly, President, Chief Executive Officer, Director
- Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
- Susanna Gatti High, Chief Operating Officer
- Eric M. Sullivan, Principal Accounting Officer, Vice President - Finance, Treasurer
- Philip D. Gregory Ph.D., Chief Scientific Officer
- David M. Davidson M.D., Chief Medical Officer
- Jason F. Cole Esq., Chief Legal Officer, Secretary
- John O. Agwunobi M.D., Director
- Douglas A. Melton, Director
Who owns bluebird bio stock?
bluebird bio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Taylor Wealth Management Partners (0.09%), Woodstock Corp (0.02%), Fox Run Management L.L.C. (0.02%), Aperio Group LLC (0.01%), Winslow Evans & Crocker Inc. (0.01%) and Bank of Montreal Can (0.00%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.
Who sold bluebird bio stock? Who is selling bluebird bio stock?
bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.
Who bought bluebird bio stock? Who is buying bluebird bio stock?
How do I buy bluebird bio stock?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is bluebird bio's stock price today?
One share of bluebird bio stock can currently be purchased for approximately $96.05.
MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for bluebird bio (NASDAQ:BLUE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 4 Hold Ratings, 11 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.53) |
| Consensus Price Target: | $98.82 (2.88% upside) |
Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $105.00 -> $103.00 | Low |  |
| 7/6/2017 | Jefferies Group LLC | Reiterated Rating | Buy | | Low | |
| 6/30/2017 | BTIG Research | Downgrade | Buy -> Neutral | $37.05 -> $108.25 | Medium | |
| 6/26/2017 | Janney Montgomery Scott | Set Price Target | Buy | $125.00 | N/A | |
| 6/24/2017 | Cantor Fitzgerald | Set Price Target | Sell | $37.00 -> $39.00 | Low | |
| 6/23/2017 | Cowen and Company | Reiterated Rating | Buy | | Low | |
| 6/23/2017 | Wedbush | Reiterated Rating | Outperform | $121.00 -> $100.00 | Low | |
| 6/16/2017 | Standpoint Research | Reiterated Rating | Buy -> Reduce | $110.00 | Low | |
| 6/6/2017 | BMO Capital Markets | Reiterated Rating | Buy | $108.00 | High | |
| 6/5/2017 | Bank of America Corporation | Reiterated Rating | Hold | $95.00 | High | |
| 6/2/2017 | Maxim Group | Upgrade | Hold -> Buy | $100.00 | High | |
| 2/23/2017 | Roth Capital | Set Price Target | Hold | $71.00 | N/A | |
| 12/7/2016 | J P Morgan Chase & Co | Reiterated Rating | Buy | $120.00 | N/A | |
| 12/1/2016 | Leerink Swann | Boost Price Target | Outperform | $80.00 -> $85.00 | N/A | |
| 11/30/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $95.00 | N/A | |
| 10/15/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | $135.00 | N/A | |
| 10/14/2016 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | N/A | |
| 5/5/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 11/5/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $162.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for bluebird bio (NASDAQ:BLUE)Earnings History by Quarter for bluebird bio (NASDAQ BLUE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | ($1.66) | | | | | N/A | |
| 5/3/2017 | Q1 2017 | ($1.76) | ($1.68) | $1.51 million | $6.83 million | View | N/A | |
| 2/22/2017 | Q4 2016 | ($1.86) | ($1.88) | $1.76 million | $1.55 million | View | N/A | |
| 11/2/2016 | Q3 2016 | ($1.59) | ($2.07) | $1.82 million | $1.55 million | View | N/A | |
| 8/3/2016 | Q2 | ($1.44) | ($1.59) | $2.01 million | $1.55 million | View | N/A | |
| 5/4/2016 | Q1 | ($1.23) | ($1.52) | $4.50 million | $1.50 million | View | N/A | |
| 2/24/2016 | Q4 | ($1.11) | ($1.29) | $3.21 million | $1.47 million | View | N/A | |
| 11/4/2015 | Q3 | ($0.96) | ($1.18) | $5.63 million | $1.30 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.78) | ($1.57) | $8.60 million | $4.94 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.68) | ($0.76) | $6.20 million | $6.30 million | View | N/A | |
| 2/25/2015 | Q414 | ($0.62) | ($0.66) | $6.20 million | $6.30 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.52) | ($0.61) | $6.20 million | $6.40 million | View | N/A | |
| 8/12/2014 | Q214 | ($0.45) | ($0.06) | $6.15 million | $6.30 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.32) | ($0.44) | $6.23 million | $6.30 million | View | N/A | |
| 3/5/2014 | | ($0.31) | ($0.34) | | | View | N/A | |
| 11/12/2013 | Q3 | ($0.25) | ($0.26) | $5.59 million | $6.39 million | View | N/A | |
| 8/8/2013 | Q213 | ($0.35) | ($2.13) | $4.85 million | $6.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for bluebird bio (NASDAQ:BLUE)2017 EPS Consensus Estimate: ($7.23)
2018 EPS Consensus Estimate: ($6.91)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($1.88) | ($1.79) | ($1.83) |
| Q2 2017 | 5 | ($1.89) | ($1.60) | ($1.75) |
| Q3 2017 | 5 | ($1.94) | ($1.67) | ($1.79) |
| Q4 2017 | 5 | ($2.03) | ($1.75) | ($1.86) |
| Q1 2018 | 1 | ($1.78) | ($1.78) | ($1.78) |
| Q2 2018 | 1 | ($1.68) | ($1.68) | ($1.68) |
| Q3 2018 | 1 | ($1.71) | ($1.71) | ($1.71) |
| Q4 2018 | 1 | ($1.74) | ($1.74) | ($1.74) |
(Data provided by Zacks Investment Research)
Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/10/2017 | Jeffrey T Walsh | Insider | Sell | 2,500 | $99.89 | $249,725.00 | |
| 7/7/2017 | David Davidson | Insider | Sell | 1,200 | $100.49 | $120,588.00 | |
| 7/6/2017 | Philip D Gregory | Insider | Sell | 2,250 | $103.83 | $233,617.50 | |
| 7/5/2017 | David Davidson | Insider | Sell | 5,000 | $105.28 | $526,400.00 | |
| 6/29/2017 | Eric Sullivan | Insider | Sell | 6,787 | $108.96 | $739,511.52 | |
| 6/27/2017 | Nick Leschly | Insider | Sell | 25,000 | $108.05 | $2,701,250.00 | |
| 6/23/2017 | Daniel Lynch | Director | Sell | 4,000 | $109.09 | $436,360.00 | |
| 6/20/2017 | Daniel Lynch | Director | Sell | 2,500 | $120.03 | $300,075.00 | |
| 6/7/2017 | Jason Cole | Insider | Sell | 17,245 | $100.22 | $1,728,293.90 | |
| 6/6/2017 | Daniel Lynch | Director | Sell | 2,263 | $100.14 | $226,616.82 | |
| 6/6/2017 | Philip D Gregory | Insider | Sell | 1,500 | $99.04 | $148,560.00 | |
| 6/5/2017 | David Davidson | Insider | Sell | 1,000 | $90.00 | $90,000.00 | |
| 5/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $80.00 | $160,000.00 | |
| 4/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $90.01 | $90,010.00 | |
| 4/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $86.75 | $173,500.00 | |
| 4/10/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $87.38 | $109,225.00 | |
| 4/3/2017 | David Davidson | Insider | Sell | 3,000 | $90.89 | $272,670.00 | |
| 3/27/2017 | Daniel Lynch | Director | Sell | 3,000 | $88.12 | $264,360.00 | |
| 3/16/2017 | Daniel Lynch | Director | Sell | 237 | $100.07 | $23,716.59 | |
| 3/16/2017 | Jason Cole | Insider | Sell | 4,930 | $100.07 | $493,345.10 | |
| 3/3/2017 | John Maraganore | Director | Sell | 13,839 | $85.02 | $1,176,591.78 | |
| 2/15/2017 | Daniel Lynch | Director | Sell | 150 | $80.22 | $12,033.00 | |
| 2/15/2017 | Jason Cole | Insider | Sell | 666 | $80.22 | $53,426.52 | |
| 2/14/2017 | Daniel Lynch | Director | Sell | 850 | $80.01 | $68,008.50 | |
| 2/14/2017 | Jason Cole | Insider | Sell | 3,772 | $80.01 | $301,797.72 | |
| 1/31/2017 | James Mandell | Director | Sell | 8,000 | $75.04 | $600,320.00 | |
| 1/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $70.09 | $70,090.00 | |
| 1/27/2017 | David Davidson | Insider | Sell | 6,000 | $69.02 | $414,120.00 | |
| 1/5/2017 | Jason Cole | Insider | Sell | 549 | $67.10 | $36,837.90 | |
| 10/3/2016 | Eric Sullivan | Insider | Sell | 416 | $67.00 | $27,872.00 | |
| 9/13/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 8/3/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 7/27/2016 | Eric Sullivan | Insider | Sell | 2,912 | $55.01 | $160,189.12 | |
| 7/20/2016 | Eric Sullivan | Insider | Sell | 2,807 | $45.04 | $126,427.28 | |
| 7/15/2016 | David Davidson | Insider | Sell | 1,000 | $45.08 | $45,080.00 | |
| 6/16/2016 | Philip D Gregory | Insider | Sell | 2,931 | $39.52 | $115,833.12 | |
| 6/15/2016 | David Davidson | Insider | Sell | 1,000 | $40.11 | $40,110.00 | |
| 5/16/2016 | David Davidson | Insider | Sell | 1,000 | $38.73 | $38,730.00 | |
| 4/15/2016 | David Davidson | Insider | Sell | 1,000 | $49.63 | $49,630.00 | |
| 3/15/2016 | David Davidson | Insider | Sell | 1,000 | $46.13 | $46,130.00 | |
| 2/16/2016 | David Davidson | insider | Sell | 1,000 | $45.18 | $45,180.00 | |
| 1/15/2016 | David Davidson | insider | Sell | 1,000 | $44.39 | $44,390.00 | |
| 12/15/2015 | David Davidson | insider | Sell | 1,000 | $58.55 | $58,550.00 | |
| 12/8/2015 | Nick Leschly | CEO | Buy | 9,682 | $51.75 | $501,043.50 | |
| 11/16/2015 | David Davidson | insider | Sell | 2,000 | $70.99 | $141,980.00 | |
| 11/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $74.60 | $820,600.00 | |
| 10/15/2015 | David Davidson | insider | Sell | 2,000 | $79.70 | $159,400.00 | |
| 10/12/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $88.06 | $968,660.00 | |
| 10/9/2015 | Jason Cole | SVP | Sell | 5,000 | $86.91 | $434,550.00 | |
| 10/5/2015 | Daniel Lynch | Director | Sell | 3,000 | $100.41 | $301,230.00 | |
| 9/17/2015 | Daniel Lynch | Director | Sell | 1,500 | $140.06 | $210,090.00 | |
| 9/15/2015 | David Davidson | insider | Sell | 2,000 | $129.98 | $259,960.00 | |
| 9/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $130.02 | $1,430,220.00 | |
| 9/9/2015 | Jason Cole | SVP | Sell | 2,000 | $136.56 | $273,120.00 | |
| 9/8/2015 | Daniel Lynch | Director | Sell | 7,000 | $132.75 | $929,250.00 | |
| 9/8/2015 | Nick Leschly | CEO | Sell | 125,000 | $135.24 | $16,905,000.00 | |
| 9/1/2015 | James Mandell | Director | Sell | 1,500 | $125.96 | $188,940.00 | |
| 7/20/2015 | Eric Sullivan | Insider | Sell | 1,126 | $163.36 | $183,943.36 | |
| 7/15/2015 | David Davidson | Insider | Sell | 2,000 | $165.96 | $331,920.00 | |
| 7/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $158.63 | $1,744,930.00 | |
| 7/9/2015 | Jason Cole | SVP | Sell | 5,000 | $158.19 | $790,950.00 | |
| 6/15/2015 | David Davidson | Insider | Sell | 2,000 | $183.34 | $366,680.00 | |
| 6/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $179.70 | $1,976,700.00 | |
| 6/1/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $190.25 | $2,853,750.00 | |
| 4/20/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $126.03 | $1,890,450.00 | |
| 4/15/2015 | David Davidson | Insider | Sell | 2,000 | $130.18 | $260,360.00 | |
| 4/10/2015 | Jeffrey T Walsh | COO | Sell | 21,000 | $126.21 | $2,650,410.00 | |
| 4/2/2015 | Eric Sullivan | Insider | Sell | 2,998 | $117.81 | $353,194.38 | |
| 3/10/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $110.06 | $1,155,630.00 | |
| 3/2/2015 | David Davidson | Insider | Sell | 4,000 | $94.84 | $379,360.00 | |
| 1/12/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $103.57 | $1,087,485.00 | |
| 1/2/2015 | David Davidson | Insider | Sell | 4,000 | $90.01 | $360,040.00 | |
| 12/19/2014 | John Maraganore | Director | Buy | 2,352 | $85.00 | $199,920.00 | |
| 12/10/2014 | Jeffrey T Walsh | COO | Sell | 43,500 | $78.06 | $3,395,610.00 | |
| 12/8/2014 | David Davidson | Insider | Sell | 15,000 | $46.10 | $691,500.00 | |
| 12/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.65 | $124,950.00 | |
| 12/1/2014 | Mitchell H Finer | Insider | Sell | 18,000 | $39.70 | $714,600.00 | |
| 12/1/2014 | Nick Leschly | CEO | Sell | 2,417 | $39.70 | $95,954.90 | |
| 11/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.68 | $125,040.00 | |
| 11/3/2014 | Nick Leschly | CEO | Sell | 25,000 | $41.68 | $1,042,000.00 | |
| 10/24/2014 | Nick Leschly | CEO | Sell | 33,900 | $40.22 | $1,363,458.00 | |
| 10/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.16 | $248,700.00 | |
| 10/9/2014 | Steven Gillis | Director | Sell | 115,000 | $35.25 | $4,053,750.00 | |
| 10/8/2014 | Mitchell H Finer | Insider | Sell | 34,518 | $33.52 | $1,157,043.36 | |
| 10/7/2014 | Steven Gillis | Director | Sell | 57,435 | $35.43 | $2,034,922.05 | |
| 10/2/2014 | Steven Gillis | Director | Sell | 91,165 | $35.28 | $3,216,301.20 | |
| 10/1/2014 | David Davidson | Insider | Sell | 3,000 | $34.55 | $103,650.00 | |
| 10/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $34.55 | $276,400.00 | |
| 9/12/2014 | Robert I Tepper | Director | Sell | 125,000 | $36.54 | $4,567,500.00 | |
| 9/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $37.02 | $277,650.00 | |
| 9/2/2014 | David Davidson | Insider | Sell | 3,000 | $38.00 | $114,000.00 | |
| 9/2/2014 | Nick Leschly | CEO | Sell | 10,300 | $38.45 | $396,035.00 | |
| 8/11/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $34.26 | $256,950.00 | |
| 8/1/2014 | David Davidson | Insider | Sell | 3,000 | $33.62 | $100,860.00 | |
| 8/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $33.62 | $268,960.00 | |
| 7/14/2014 | John Maraganore | Director | Buy | 2,941 | $34.00 | $99,994.00 | |
| 7/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.20 | $249,000.00 | |
| 7/3/2014 | Nick Leschly | CEO | Sell | 22,283 | $39.86 | $888,200.38 | |
| 7/1/2014 | David Davidson | Insider | Sell | 3,000 | $39.55 | $118,650.00 | |
| 6/20/2014 | Nick Leschly | CEO | Sell | 17,075 | $40.06 | $684,024.50 | |
| 6/16/2014 | Jeffrey T Walsh | COO | Sell | 1,500 | $39.86 | $59,790.00 | |
| 6/16/2014 | Mitchell H Finer | Insider | Sell | 10,000 | $39.84 | $398,400.00 | |
| 6/16/2014 | Nick Leschly | CEO | Sell | 42,925 | $40.02 | $1,717,858.50 | |
| 6/10/2014 | Jeffrey T Walsh | COO | Sell | 6,000 | $24.23 | $145,380.00 | |
| 6/2/2014 | Mitchell H Finer | Insider | Sell | 8,000 | $22.21 | $177,680.00 | |
| 6/2/2014 | Nick Leschly | CEO | Sell | 5,000 | $22.21 | $111,050.00 | |
| 5/14/2014 | Jeffrey Walsh | COO | Sell | 1,500 | $20.03 | $30,045.00 | |
| 5/12/2014 | Jeffrey Walsh | COO | Sell | 4,500 | $18.93 | $85,185.00 | |
| 5/1/2014 | David Davidson | Insider | Sell | 4,000 | $19.85 | $79,400.00 | |
| 5/1/2014 | Nick Leschly | CEO | Sell | 5,000 | $20.07 | $100,350.00 | |
| 4/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.29 | $127,740.00 | |
| 1/22/2014 | Linda Bain | VP | Sell | 2,500 | $25.11 | $62,775.00 | |
| 1/17/2014 | Robert Tepper | Director | Sell | 307,000 | $22.43 | $6,886,010.00 | |
| 1/16/2014 | Mitchell Finer | Insider | Sell | 10,000 | $23.52 | $235,200.00 | |
| 1/14/2014 | Robert Tepper | Director | Sell | 340,000 | $21.90 | $7,446,000.00 | |
| 1/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.98 | $131,880.00 | |
| 1/3/2014 | David Davidson | Insider | Sell | 15,000 | $20.88 | $313,200.00 | |
| 1/3/2014 | Linda Bain | VP | Sell | 5,000 | $20.89 | $104,450.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
| Source: |
|
| Date | Headline |
|---|
 | Commit To Buy bluebird bio At $50, Earn 10.4% Using Options
www.nasdaq.com - July 21 at 4:59 PM |
 | Sanderson Farms, Inc. Names Suzanne Mestayer To Board Of Directors
www.thestreet.com - July 20 at 6:11 PM |
 | bluebird bio, Inc. (BLUE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 18 at 7:58 PM |
 | ETFs with exposure to bluebird bio, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 6:30 PM |
 | Pioneering Cancer Gene Therapy by Novartis Backed by U.S. Panel
www.nytimes.com - July 13 at 10:36 PM |
 | FDA Backs Pioneering Gene-Altering Cancer Treatment - HuffPost
www.huffingtonpost.com - July 13 at 5:35 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 2,500 Shares of Stock
www.americanbankingnews.com - July 12 at 8:16 PM |
 | Opinion: Technical trading: These four stocks are breaking out of their pattern - MarketWatch
www.marketwatch.com - July 12 at 5:11 PM |
 | FDA panel backs Novartis' pioneering new cancer gene therapy - Reuters
www.reuters.com - July 12 at 5:11 PM |
 | SunTrust bullish on bluebird bio - Seeking Alpha
seekingalpha.com - July 12 at 5:11 PM |
| Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug
finance.yahoo.com - July 12 at 5:11 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Expected to Post Quarterly Sales of $5.70 Million
www.americanbankingnews.com - July 12 at 9:36 AM |
| A Junior Freak Out
www.nasdaq.com - July 12 at 2:57 AM |
| bluebird bio, Inc. (BLUE) Insider Sells $120,588.00 in Stock
www.americanbankingnews.com - July 11 at 8:20 PM |
| bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : July 11, 2017
finance.yahoo.com - July 11 at 4:54 PM |
| Morgan Stanley Reiterates Equal Weight Rating for bluebird bio, Inc. (BLUE)
www.americanbankingnews.com - July 10 at 9:40 PM |
| Philip D. Gregory Sells 2,250 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
www.americanbankingnews.com - July 10 at 8:12 PM |
| -$1.63 Earnings Per Share Expected for bluebird bio, Inc. (NASDAQ:BLUE) This Quarter
www.americanbankingnews.com - July 10 at 8:10 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
| Jefferies Group LLC Reaffirms "Buy" Rating for bluebird bio, Inc. (NASDAQ:BLUE)
www.americanbankingnews.com - July 6 at 5:20 PM |
| bluebird bio, Inc. (BLUE) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - July 4 at 8:28 PM |
| bluebird bio, Inc. (BLUE) Receives "Buy" Rating from BTIG Research
www.americanbankingnews.com - July 2 at 1:20 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - July 1 at 8:04 AM |
 | Morning Movers: Tesla Gains on Musk Tweet; Bluebird Bio Falls - Barron's
www.barrons.com - June 30 at 4:41 PM |
| Bluebird Bio: Too Much Good News? - Barron's
www.barrons.com - June 30 at 4:41 PM |
| Bluebird Bio: Too Much Good News?
finance.yahoo.com - June 30 at 4:41 PM |
| The Cure For Cancer? Look At Your Blood
finance.yahoo.com - June 30 at 4:41 PM |
| Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?
finance.yahoo.com - June 30 at 4:40 PM |
| bluebird bio, Inc. (BLUE) Insider Sells $739,511.52 in Stock
www.americanbankingnews.com - June 30 at 4:36 PM |
| bluebird bio, Inc. (BLUE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 30 at 9:54 AM |
| bluebird bio, Inc. to Post Q2 2017 Earnings of ($1.60) Per Share, Leerink Swann Forecasts (BLUE)
www.americanbankingnews.com - June 30 at 8:06 AM |
| BTIG Research Lowers bluebird bio, Inc. (BLUE) to Neutral
www.americanbankingnews.com - June 30 at 7:54 AM |
| Nick Leschly Sells 25,000 Shares of bluebird bio, Inc. (BLUE) Stock
www.americanbankingnews.com - June 29 at 4:29 PM |
| bluebird bio Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 28 at 4:41 PM |
 | Bluebird Bio Gears Up for $350 Million Offering - 24/7 Wall St.
247wallst.com - June 27 at 9:09 PM |
| Daniel Lynch Sells 4,000 Shares of bluebird bio, Inc. (BLUE) Stock
www.americanbankingnews.com - June 27 at 7:51 PM |
 | bluebird bio (BLUE) Reports Topline Interim Data from Starbeam Study of Lenti-D Drug Product in CALD
www.streetinsider.com - June 27 at 4:09 PM |
| bluebird bio (BLUE) Announces $350M Proposed Share Offering - StreetInsider.com
www.streetinsider.com - June 27 at 2:38 AM |
| bluebird bio (BLUE) Reports Topline Interim Data from Starbeam ... - StreetInsider.com
www.streetinsider.com - June 26 at 9:35 PM |
| BRIEF-Bluebird bio reports updated clinical data from starbeam study - Reuters
www.reuters.com - June 26 at 9:35 PM |
| bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD)
finance.yahoo.com - June 26 at 4:33 PM |
| bluebird bio Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 26 at 4:33 PM |
| Analysts Offer Predictions for bluebird bio, Inc.'s FY2018 Earnings (BLUE)
www.americanbankingnews.com - June 26 at 10:42 AM |
| bluebird bio, Inc. (BLUE) Given a $39.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - June 25 at 11:40 PM |
 | Drug Product at European Hematology Association (EHA) Annual Meeting - Business Wire (press release)
www.businesswire.com - June 24 at 2:40 AM |
| bluebird bio, Inc. (BLUE) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - June 23 at 11:28 PM |
| bluebird bio, Inc. (BLUE) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - June 23 at 5:18 PM |
| bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting
finance.yahoo.com - June 23 at 4:34 PM |
| bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting
finance.yahoo.com - June 23 at 4:34 PM |
| bluebird bio's (BLUE) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - June 23 at 4:32 PM |
bluebird bio (BLUE) Chart for Sunday, July, 23, 2017
